.gif)
Bristol-Myers Squibb Company (NYSE:BMY) announced that they have entered into a collaboration agreement with The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM research program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
As part of the I-O RPM program, Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center will conduct a range of early phase clinical studies and Bristol-Myers Squibb will fund positions within The Johns Hopkins University School of Medicine fellowship program.
“Johns Hopkins has been a long-time collaborator with Bristol-Myers Squibb in immuno-oncology research,” said Laura Bessen, M.D., head of U.S. Medical, Bristol-Myers Squibb. “We look forward to working with them as part of the I-O RPM research program as we continue to advance the science in this innovative field of cancer research and development, particularly among subpopulations of patients with high risk, poor prognostic cancers.”
Subscribe to PharmaTutor News Alerts by Email >>
